Research Study Summary
MEDI-551-1088 - A Phase 2 Randomized Open-Label Study of MEDI-551 in Adults with Relapsed or Refractory Diffused Large B-Cell Lymphoma
Objective - overall response rate, including partial response and complete responsem of subjects trated with MEDI-551 when used in combination with a chemotherapy regimen containing either ifosfamide, carboplatin, and etoposide (ICE) or dexamethasone cytarabine, and cisplatin (DHAP) versus rituximab in combination with ICE or DHAP in subjects with relapsed or refractory diffuse large B-cell lymphoma
Patient Inclusion Criteria: See www.hsc.wvu.edu/mbrcc/ctru/ for additional information.
Patient Exclusion Criteria: See www.hsc.wvu.edu/mbrcc/ctru/ for additional information.
To Learn more
CW ID: 183172
Date Last Changed:
July 17, 2013
Clinical Trial Snapshot
- Both Male and Female
- Overall Status
- Facility Type
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.